The technology

A number of sight-threatening diseases are caused by the inability of the retina to detect light due to damaged photoreceptor cells. Retinal optogenetics involves (i) the insertion of a gene encoding a protein that confers light responsiveness to target cells, and (ii) the use of a medical device to deliver light at the right intensity and wavelength in order to stimulate the transduced retinal cells so that the cells transmit the signal to the brain.

We use gene therapy to confer a photoreceptive function to our target cells: the healthy and preserved RGCs in diseases such as RP. We combine the gene therapy with the use of our specially-developed external wearable device, designed as goggles, to amplify the light stimulation upon the transduced neuronal cells. The light, now at the right intensity and wavelength to stimulate the transduced neuronal cells, results in expanded vision restoration.

Product applications

  • Our GS030 product candidate uses optogenetics with an external wearable medical device in the form of biomimetic goggles to provide the light source and stimulation algorithms. The device is composed of:
    • A visual interface integrating an asynchronous time-based image sensor (ATIS, also called a neuromorphic video camera), and a digital micromirror array (DMD) driven by a microprocessor, that convey the visual information signal and light to the macula;
      and
    • A pocket computer the size of a portable telephone connected to an optoelectronic stimulation device, which processes the visual information and controls a light source in order to encode and amplify corresponding light signals at a specific wavelength
  • We believe that this technology would be immediately transferable to any disease in which photoreceptors are lost while RGCs remain